LPCAT1 and non-small cell lung carcinoma: These results demonstrated that MYC might act as a downstream regulator of PI3K/AKT pathway, and LPCAT1 might promote NSCLC progression, at least in part, through the PI3K/AKT/MYC signaling pathway.